| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
The overexpression of lymphocyte Kv1.3-channels contributes to the progression of chronic kidney disease (CKD) by promoting cellular proliferation and interstitial fibrosis. In our patch-clamp studies, since benidipine and simvastatin were highly potent as Kv1.3-channel inhibitors, they could exert therapeutic efficacy in the progression of CKD. Therefore, using a rat model with advanced stage chronic renal failure (advanced CRF), we examined the effects of these drugs on the histopathological features of the kidneys and the cortical expression of pro-inflammatory cytokines. In the cortical interstitium of advanced CRF rat kidneys, these drugs significantly ameliorated the progression of renal fibrosis. Both drugs reduced the number of proliferating leukocytes with a significant decrease in the pro-inflammatory cytokine expression. The studies indicated the therapeutic potency of Kv1.3-channel inhibitors in the treatment or the prevention of chronic inflammatory disease.
|
